Cytek Biosciences, Inc. CTKB Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s stock issuance proceeds?
- Cytek Biosciences, Inc. (CTKB) reported stock issuance proceeds of $21K in Q1 2026.
- How has Cytek Biosciences, Inc.'s stock issuance proceeds changed year-over-year?
- Cytek Biosciences, Inc.'s stock issuance proceeds decreased by 46.2% year-over-year, from $39K to $21K.
- What is the long-term trend for Cytek Biosciences, Inc.'s stock issuance proceeds?
- Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s stock issuance proceeds has grown at a -15.6% compound annual growth rate (CAGR), from $642K to $325K.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.